Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending June 30, 2023 was -3.24 (a -62.31% decrease compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA decreased by -96.59%
- Annual Net Debt/EBITDA for 2022 was -30.17 (a -5575.79% decrease from previous year)
- Annual Net Debt/EBITDA for 2021 was 0.55 (a 17.59% increase from previous year)
- Annual Net Debt/EBITDA for 2020 was 0.47 (a -83.41% decrease from previous year)
Visit stockrow.com/EBS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of Emergent Biosolutions Inc.
Most recent Net Debt/EBITDAof EBS including historical data for past 10 years.Interactive Chart of Net Debt/EBITDA of Emergent Biosolutions Inc.
Emergent Biosolutions Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | -3.24 | -8.61 | – | – | – |
| 2022 | -26.78 | -95.13 | -17.62 | 10.37 | -30.17 |
| 2021 | 0.86 | -494.33 | 8.34 | 2.49 | 0.55 |
| 2020 | 0.9 | 5.1 | 3.37 | 35.12 | 0.47 |
| 2019 | 6.05 | 6.9 | 29.27 | 6051.0 | 2.82 |
| 2018 | 18.34 | -9.7 | -2.25 | -52.13 | 4.46 |
| 2017 | -2.46 | -1.62 | -3.63 | -0.87 | -0.98 |
| 2016 | -0.38 | -1.12 | -12.49 | -3.13 | -0.02 |
| 2015 | -0.65 | -0.78 | 1.26 | -1.74 | -0.35 |
| 2014 | -0.35 | 0.28 | 5.08 | -4.87 | -0.24 |
| 2013 | -4.09 | -4.85 | -5.06 | 7.47 | -1.9 |
| 2012 | -2.86 | -10.72 | – | – | -1.92 |
Business Profile of Emergent Biosolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic